Date and Time:  Friday 22\textsuperscript{nd} January 2016, 1000 – 1600

Place:  Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ

Present:  GDG members
Bruce Guthrie (BG) – Chair
Alaster Rutherford (AF) – Pharmacist
Andrew Clegg (AC) – Geriatrician
Cate Seton-Jones (CSJ) – Palliative Care Specialist
Emily Lam (EL) – Lay member
Jonathan Inglesfield (JI) – General Practitioner
John Hindle (JH) – Geriatrician
Nina Barnett (NB) – Pharmacist
Rupert Payne (RP) – General practitioner/Pharmacologist
Sam Barnett-Cormack (SBC) – Lay member
Carolyn Chew-Graham (CCG) – General practitioner

NCGC
Tamara Diaz (TD) – Project Manager
Neil Askew (NA) – Health Economist
Elisabetta Fenu (EF) – Senior Health Economist
Caroline Farmer (CF) – Senior Research Fellow
James Gilbert (JG) – Research Fellow
Hannah K (HK) – Research Fellow
Norma O’Flynn (NOC) – Guideline Lead/Clinical Director

NICE
Anne Louise Clayton (ALC) – NICE Editor
Yolanda Martinez (YM) – Technical Analyst (Observer)
Caroline Keir (CK) – Guidelines Commissioning Manager
Stephanie Birtles (SB) – Quality Indicators programme

Apologies:  David Kernick (DK) – General Practitioner
Notes

1. **Introduction, apologies and minutes**
The chair welcomed the group to the tenth meeting of the GDG. Apologies were received from CK. The minutes from the previous meeting were signed off as accurate.

2. **Declaration of interests**
The Chair reviewed and requested updates to the declarations of interest register. The declarations of interest received for this meeting included:

<table>
<thead>
<tr>
<th>Initials</th>
<th>Declaration</th>
<th>Classification</th>
<th>Chair’s action</th>
</tr>
</thead>
<tbody>
<tr>
<td>NB</td>
<td>Talk on respiratory medications and adherence, funded for by drug company. Talk at upcoming congress on medications and dysphagia, aphasia and patient centred polypharmacy. Organisation receives funding from pharmaceutical companies. Talk on pharmacy management on medicines optimisation and adherence. Organisation receives funding from pharmaceutical companies.</td>
<td>Personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>RP</td>
<td>Has taken on a paid role as clinical editor for Prescriber Journal (from January 2016). Has also accepted a commitment (remunerated) to talk at a Clinical Pharmacy Congress in London in April 2016.</td>
<td>Personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
</tbody>
</table>
3. **Evidence reviews: further rerun results**  
The technical team presented further rerun results for the following reviews:

- Risk tools – admission to care facilities
- Risk tools – unplanned hospital admissions
- Stopping drugs – statins
- Interventions – Holistic Assessment (Health economic update only)

After presentation of the evidence the GDG discussed the reviews and considered the impact of the new data on the guideline’s draft recommendations.

4. **Health economic update**  
An update on the health economic model was provided for the GDG’s information.

5. **Draft recommendations**  
The GDG members reviewed the draft recommendations for the guideline.

6. **Data on effectiveness of treatments**  
JG thanked the GDG for feedback provided on the database and presented an update to the group on the subsequent changes made.

7. **Draft research recommendations**  
The GDG members were asked to review the circulated draft research recommendations and provide any further feedback to the technical team ahead of consultation.

8. **AOB**  
The group was advised that the technical team will contact them shortly with final dates for the guideline’s editorial meeting in April. There were no further items for the group’s attention.

9. **Date, time and venue of the next meeting**  
10th June 2016, 1000–1600, Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ.